How much did SenzaGen achieve in EBIT for the current year?
In the current year, SenzaGen has achieved an EBIT of -12.36 M SEK.
SenzaGen EBIT 2024
SenzaGen EBIT
-12.36 M SEK
SenzaGen Dividend yield
Ticker
SENZA.ST
ISIN
SE0010219626
WKN
A2DX79
In 2024, SenzaGen's EBIT was -12.36 M SEK, a -17.42% increase from the -14.97 M SEK EBIT recorded in the previous year.
The SenzaGen EBIT history
| YEAR | EBIT (undefined SEK) |
|---|---|
| 2026e | 14.94 |
| 2025e | 1.03 |
| 2024e | -12.36 |
| 2023 | -14.97 |
| 2022 | -20.19 |
| 2021 | -31.53 |
| 2020 | -27.1 |
| 2019 | -37.93 |
| 2018 | -20.73 |
| 2017 | -16.61 |
| 2016 | -11.34 |
| 2015 | -4.75 |
| 2014 | 0.33 |
SenzaGen Aktienanalyse
What does SenzaGen do?
SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing SenzaGen's EBIT
SenzaGen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of SenzaGen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
SenzaGen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in SenzaGen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about SenzaGen Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company SenzaGen.
How has the EBIT of SenzaGen developed in recent years?
The EBIT of SenzaGen has increased by -17.424% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company SenzaGen?
The EBIT of SenzaGen is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does SenzaGen pay?
Over the past 12 months, SenzaGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SenzaGen is expected to pay a dividend of 0 SEK.
What is the dividend yield of SenzaGen?
The current dividend yield of SenzaGen is .
When does SenzaGen pay dividends?
SenzaGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of SenzaGen?
SenzaGen paid dividends every year for the past 0 years.
What is the dividend of SenzaGen?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is SenzaGen located?
SenzaGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von SenzaGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of SenzaGen from 5/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/6/2024.
When did SenzaGen pay the last dividend?
The last dividend was paid out on 5/6/2024.
What was the dividend of SenzaGen in the year 2023?
In the year 2023, SenzaGen distributed 0 SEK as dividends.
In which currency does SenzaGen pay out the dividend?
The dividends of SenzaGen are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von SenzaGen
Our stock analysis for SenzaGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SenzaGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
